As the first FDA-approved breakthrough therapy targeting amyloid-beta, Aduhelm (Aducanumab) provides a new treatment option for patients with Alzheimer's disease.
How Effective is Aduhelm (Aducanumab) in Treatment?
Innovation in Targeting Amyloid-Beta
Aducanumab is a humanized monoclonal antibody that exerts its effects by specifically targeting both soluble and insoluble aggregated forms of amyloid-beta.
Clinical studies have shown that this drug can significantly reduce the burden of amyloid-beta plaques in patients' brains, which is one of the characteristic pathological changes of Alzheimer's disease.
Assessment of Clinical Benefits
In key clinical trials, Aducanumab has demonstrated the potential to slow down the clinical progression of the disease.
Through the evaluation of comprehensive indicators of cognitive function and daily living abilities, patients receiving treatment showed a slower rate of cognitive decline.
Multidimensional Improvements
Aducanumab may also have a regulatory effect on pathological processes related to tau protein.
Studies have indicated that the level of phosphorylated tau protein in the cerebrospinal fluid of patients decreases after drug treatment, suggesting that the drug may have a comprehensive regulatory effect on the multiple pathological processes of Alzheimer's disease.
Who is Aduhelm (Aducanumab) Suitable for?
Patients with Alzheimer's Disease at Specific Stages
Aduhelm is currently approved for the treatment of Alzheimer's disease, and is particularly suitable for patients in the stages of mild cognitive impairment or mild dementia.
Patients Confirmed by Biomarkers
Before using Aduhelm, it is necessary to confirm the presence of amyloid-beta pathology in patients through cerebrospinal fluid testing or amyloid PET imaging.
Medication Monitoring for Aduhelm (Aducanumab)
Comprehensive Assessment Before Treatment
Before initiating Aduhelm treatment, a baseline assessment must be conducted, including a brain MRI scan to rule out intracerebral hemorrhage or large-area microhemorrhage foci.
At the same time, the patient's cognitive function status should be evaluated to establish a comparative baseline before and after treatment.
Monitoring During Treatment
Aduhelm is administered via intravenous infusion, and the dose escalation protocol must be strictly followed.
Especially in the early stage of treatment, close monitoring for Amyloid-Related Imaging Abnormalities (ARIA) is required. This adverse reaction mainly manifests as cerebral edema or microhemorrhage.
It is recommended to perform a brain MRI scan before the 7th and 12th infusions.
Management of Adverse Reactions
ARIA is the most common adverse reaction of Aduhelm. Most cases are asymptomatic, but it is necessary to be alert to related neurological symptoms such as headache and confusion.
Once symptomatic ARIA occurs, immediate evaluation should be conducted and consideration should be given to suspending drug administration.
Infusion-related reactions need to be monitored. Although severe allergic reactions are rare, they require emergency treatment.
